Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Syk, a novel therapeutic target for PTLD, drives Epstein Barr Virus B cell lymphoma growth and survival through the PI3K/Akt pathway Hatton, O. L., Lambert, S., Vaysberg, M., Krams, S. M., Esquivel, C. O., Martinez, O. M. AMER ASSOC IMMUNOLOGISTS. 2009
View details for Web of Science ID 000209763603142